Implantable Collamer Lens in the Management of Pseudophakic Ametropia.
Implantable Collamer Lens in the Management of Pseudophakic Ametropia.
复制标题
植入式 Collamer 镜片治疗假性晶状体屈光不正。
DOI：
10.3928/1081597x-20170606-02
复制
发表时间：
2017
影响因子：
2.4
通讯作者：
M. Sidky
中科院分区：
文献类型：
--
作者：
Sherif A Eissa;Mohamed M. Khafagy;M. Sidky
目的
旨在评估Visian植入式Collamer透镜（ICL）（STAAR Surgical，蒙罗维亚，CA）植入睫状沟以矫正不适合角膜屈光手术的患者的人工晶状体屈光不正。
方法
作者对18例超声乳化术后屈光异常的患者（年龄：48 - 61岁）进行了一项前瞻性非比较病例系列研究。患者接受了背驮式胶原共聚物透镜植入术：16只近视眼采用V4 C设计，2只远视眼采用V4 B设计。在所有临床对照访视时和使用Pentacam（Oculus Optikgeräte，韦茨拉尔，德国）记录ICL的位置和拱顶。记录基线和术后1周、1个月、6个月、12个月和18个月时的裸眼远视力（UDVA）、矫正远视力（CDVA）、明显屈光度等效球镜（MRSE）、眼内压（IOP）和内皮细胞计数。
结果
MRSE从术前的-3.08 ± 2.37 D改善至术后的-0.44 ± -0.23 D，平均ICL屈光度为-3.20 ± 2.90 D。平均UDVA从术前1.03 ± 0.12 logMAR改善至术后0.05 ± 0.06 logMAR（P = .00），而CDVA从术前0.47 ± 0.03 logMAR改善至术后-0.006 ± 0.02 logMAR（P = .001）。在整个18个月的随访中，没有病例发生晶状体间混浊。Scheimpflug断层扫描测量的平均ICL穹窿为451.27 ± 178.5 µm。2只眼发生急性IOP升高伴前葡萄膜炎，经局部类固醇和β受体阻滞剂控制。
结论
二次ICL植入术矫正人工晶状体屈光不正是安全的，可预测的，在所有研究的眼睛耐受性良好。[J Refract Surg. 2017;33（8）：532-537.]。
PURPOSE
To assess Visian Implantable Collamer Lens (ICL) (STAAR Surgical, Monrovia, CA) implantation in the ciliary sulcus to correct pseudophakic ametropia in patients who are not candidates for a keratorefractive procedure.
METHODS
The authors performed a prospective non-comparative case series study of 18 patients (age: 48 to 61 years) with refractive surprise after phacoemulsification. Patients underwent implantation of a piggyback collagen copolymer lens: V4C design in 16 myopic eyes and V4B design in 2 hyperopic eyes. The position and vault of the ICLs were documented at all control visits clinically and with Pentacam (Oculus Optikgeräte, Wetzlar, Germany). Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), intraocular pressure (IOP), and endothelial cell count were recorded at baseline and 1 week and 1, 6, 12, and 18 months postoperatively.
RESULTS
The MRSE improved from -3.08 ± 2.37 diopters (D) preoperatively to -0.44 ± -0.23 D postoperatively, corrected with a mean ICL power of -3.20 ± 2.90 D. The mean UDVA improved from 1.03 ± 0.12 logMAR preoperatively to 0.05 ± 0.06 logMAR postoperatively (P = .00), whereas CDVA improved from 0.47 ± 0.03 logMAR preoperatively to -0.006 ± 0.02 logMAR (P = .001) postoperatively. None of the cases developed interlenticular opacification throughout the 18-month follow-up. The mean ICL vault measured by Scheimpflug tomography was 451.27 ± 178.5 µm. Acute IOP elevation with anterior uveitis developed in 2 eyes and was controlled by topical steroids and a beta-blocker.
CONCLUSIONS
Sulcus implantation of the secondary ICL to correct pseudophakic refractive error was safe, predictable, and well tolerated in all studied eyes. [J Refract Surg. 2017;33(8):532-537.].